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Abstract 
Rationale 
Previous studies have suggested that acute exacerbations of COPD may be associated with increased 
risk of myocardial infarction and ischaemic stroke.  
Objective 
We aimed to quantify the increased risks of myocardial infarction and ischemic stroke risk associated 
with both moderate and severe acute exacerbation, and to investigate factors which may modify 
these risks. 
Methods 
We performed a self-controlled case-series to investigate the rates of myocardial infarction and 
ischemic stroke following acute exacerbation compared to stable time, within individuals. The 
participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic 
stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research 
Datalink with linked Hospital Episodes Statistics data.  
Results  
The risks of both myocardial infarction and ischemic stroke were increased in the 91 days following a 
acute exacerbation. The risks were greater following a severe exacerbation (incidence rate ratio 
(IRR) of 2.58 (95% CI 2.26 to 2.95) for myocardial infarction; and IRR 1.97 (95% CI 1.66-2.33) for 
ischemic stroke) than after a moderate exacerbation (IRR 1.58 (95% CI 1.46-1.71) for myocardial 
infarction; and IRR 1.45 (95% CI 1.33-1.57) for ischemic stroke. The relative risks of myocardial 
infarction and ischemic stroke associated with acute exacerbation were lower among those with 
more frequent exacerbations (IRR 1.42 (95% CI 1.24-1.62) vs 1.69 (95% CI 1.50-1.91) for myocardial 
infarction; and IRR 1.30 (95% CI 1.15-1.48) vs 1.68 (95% CI 1.50-1.89) for ischemic stroke). Higher 
GOLD stage associated with a lower rate of myocardial infarction (IRR 1.98 (95% CI 1.61-2.05) vs 1.69 
(95% CI 1.45-1.98)) but not for ischemic stroke. Aspirin use at baseline was associated with a lower 
risk of ischemic stroke (IRR 1.28 (95% CI 1.10-1.50) vs 1.63 (95% CI 1.47-1.80)), but not with 
myocardial infarction.  
Conclusions 
 Acute exacerbations of COPD are associated with an increased risk of myocardial infarction and 
ischemic stroke within 28 days of their onset. Several patient characteristics were identified which 
are associated with these events. 
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Introduction 
People with chronic obstructive pulmonary disease (COPD) are at increased risk of myocardial 
infarction (myocardial infarction)[1] and stroke[2], and up to one third of COPD patients die from 
cardiovascular disease[3]. This increased risk cannot be completely explained by smoking[4] and has 
been attributed to increased systemic inflammation[5].  
 
Acute exacerbations of COPD normally last several days; most are thought to be triggered by 
bacterial or viral infection[6, 7] and are associated with increased systemic inflammation[8, 9]. 
Previous work has shown that lower respiratory tract infections (LRTI) are associated with an 
increased risk of myocardial infarction in the general population[10](10). In addition, two small 
studies have suggested that there may be an increased risk of myocardial infarction following 
periods of acute exacerbation compared to stable periods[11, 12]. Frequent exacerbators (people 
who have two or more treated exacerbations per year), also seem to have a higher long term risk of 
myocardial infarction than infrequent exacerbators[11]. The relationship between acute 
exacerbation and stroke is less clear. A previous study found an increased risk of stroke following 
acute exacerbation, but this risk was delayed until 49 days after an acute exacerbation[11]. Another 
study found a slightly increased risk of stroke over a 10 year follow-up when comparing exacerbating 
to non-exacerbating COPD patients[13].  
 
The risk factors for myocardial infarction and ischemic stroke following acute exacerbation are not 
known, limiting the strategies or interventions that might mitigate this risk. Recent improvements in 
methods to identify acute exacerbation in electronic health records (EHR) mean that acute 
exacerbation can now be identified with greater sensitivity and precision[14]. Additionally, with 
linkage to secondary care records, the severity of acute exacerbations in COPD patients can be 
stratified using a health-care utilisation definition into moderate (general practitioner treated; 
primary care managed) and severe (hospitalised) events.   
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The aims of this study were therefore to: 1) characterise the magnitude and duration of myocardial 
infarction and ischemic stroke risks following acute exacerbation; 2) investigate the relationship 
between severity of acute exacerbation and myocardial infarction and ischemic stroke risk, and; 3) 
investigate whether the associations between exacerbation and both myocardial infarction and 
ischemic stroke are modified by COPD severity, prior acute exacerbation frequency, myocardial 
infarction type (STEMI or non-STEMI), comorbid cardiovascular disease, use of cardiovascular 
medicines, use of inhaled COPD maintenance therapy, or influenza vaccination at baseline.  
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Methods 
Data Sources 
We used data from the Clinical Practice Research Datalink (CPRD) linked with Hospital Episodes 
Statistics (HES) data. The CPRD is a large database of primary-care data. It contains details on more 
than 11 million patients in the UK, with over four million of these being active patients (around 7% of 
the UK population)[15]. The available data includes details on symptoms, diagnoses, tests, 
prescriptions, details on patient demographics and health behaviours, and referrals to secondary 
care. The diagnostic data in CPRD are mainly recorded using a system of Read codes, which is a 
hierarchical classification system. HES is an administrative database containing details of all episodes 
of admitted patient care in England and Wales. Data are structured into episodes of care by single 
consultants (“finished consultant episodes”), such that each hospitalisation may be involve several 
finished consultant episodes. Data are recorded using ICD-10 codes. Each finished consultant 
episode may be associated with up to 20 ICD-10 codes, with the first code generally representing the 
reason for hospitalisation. The remaining codes may represent other acute problems, or co-
morbidities. Data for about 60% of CPRD patients are linked to HES. CPRD-HES data were also linked 
to Office of National Statistics (ONS) data to determine exact date of death. 
 
Study design 
The self-controlled case-series is a within-person design developed to reduce confounding in 
observational studies. The incidence rate of an outcome following an exposure is compared to 
unexposed periods of time in the same individual, using only data for those who experience the 
outcome[16]. This method been used widely to investigate the risk of acute cardiovascular events 
associated with episodes of infection and inflammation[17, 18]. We used this design to estimate the 
incidences of myocardial infarction or ischemic stroke following the onset of acute exacerbation 
compared to stable periods. As well as being able to estimate the transient effect of an exposure, 
the major advantage of this design is that within-individual inferences are made since each subject 
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acts as their own control. This means that the design implicitly controls for the effects of fixed 
confounders such as sex, socioeconomic status and genetic factors, as well as other 
unknown/unmeasured fixed confounders. Follow-up time is accumulated in various age-bands to 
account for confounding by age.  
 
The self-controlled case-series method relies on three assumptions:  
1) That events do not change the probability of future exposures. This assumption should be 
met in our analysis, as it is not likely that having an myocardial infarction or ischemic stroke 
changes the future risk of acute exacerbation. 
2) That recurrent events are independent. As recurrent myocardial infarctions and strokes are 
not likely to be independent, we restricted the analysis to first myocardial infarction or 
stroke only.  
3) That the occurrence of the event does not censor or alter observation periods. This 
assumption may not be met as myocardial infarction and ischemic stroke are associated with 
considerable mortality. In order to assess the impact of this assumption, we conducted a 
sensitivity analysis described in the statistical methods section. In addition, we also stratified 
the 91 day risk period into smaller time segments to address this potential issue. 
 
Following a previous study[10] we made an a priori decision to include the maximum of 91 days 
following the onset of acute exacerbation as the exposure period. Additionally, we segmented this 
period into smaller periods of 1-3, 4-7, 8-14, 15-28, and 29-91 days, to determine how the relative 
risk changes over the exposure period. To reduce misclassification of acute exacerbation with 
myocardial infarction (or ischemic stroke), we created a 14-day window of pre-exposure time 
including the first day of the acute exacerbation, which was not included in either baseline or 
exposed time. The study design is shown in Figure 1.  
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Study participants were followed from January 1, 2004, date of COPD diagnosis, 35th birthdate, or 
CPRD practice “up to standard” date, whichever was later; follow-up finished on March 31, 2015, 
date of death, transfer out of practice or practice last collection date, whichever was earlier; the first 
year of follow up served as the baseline year.  
 
Study sample, exposure, co-variates, and outcomes 
The study sample was comprised of COPD patients who had at least one acute exacerbation and a 
first myocardial infarction or ischemic stroke during the study period. COPD patients were identified 
using a previously validated algorithm[19], and had a diagnostic Read code for COPD, a smoking 
history (ex or current smoker), and were age 35 or older. Patients were excluded if their CPRD 
records could not be linked to HES or ONS.  
 
We characterised acute exacerbation severity according to health care utilisation, with those 
requiring treatment from their general practitioner (GP) as “moderate” events, and those requiring 
hospitalisation as “severe” events using previously validated algorithms[14, 20]. Acute exacerbations 
that occurred within two weeks of the onset of a previous acute exacerbation were taken to be a 
continuing event.  
 
Apart from age, sex, and type of myocardial infarction, all potential effect modifiers were defined 
during the year prior to start of follow-up using CPRD data. Cardiovascular drug use (β-blocker, 
aspirin, and statins), inhaled COPD therapy use (long-acting β-agonists, long-acting muscarinic 
antagonists, and inhaled corticosteroids), and influenza vaccination status were defined by the 
presence of at least one prescription during the one year period prior to the start of follow-up. 
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Previous cardiovascular disease (stroke, heart failure, and angina for the myocardial infarction 
analysis; and atrial fibrillation, angina and previous myocardial infarction for the stroke analysis) was 
defined as any code suggesting one of these conditions was diagnosed at any time prior to follow up 
start. GOLD grade of airflow limitation was defined using spirometry results from the year prior to 
the start of follow-up. Study participants were dichotomised into exacerbation frequency phenotype 
categories depending on the number of exacerbations in the one year prior to follow-up start, we 
also expressed exacerbation frequency during this time in terms of actual number of events (0, 1, 2, 
≥3). The main analyses of the associations between acute exacerbation and the risks of myocardial 
infarction or ischemic stroke within 91 days were stratified by potential effect modifiers.  
 
Myocardial infarction and stroke events were defined using both primary care (CPRD) and hospital 
data (HES). Read codes were used to define myocardial infarction and ischemic stroke in CPRD 
(supplementary material). In HES, myocardial infarctions and ischemic stroke were defined as an 
ICD-10 code for myocardial infarction or ischemic stroke in the first position of a finished consultant 
episode. The date of myocardial infarction or ischemic stroke was taken as the date of the start of 
the finished consultant episode containing the myocardial infarction or ischemic stroke code, rather 
than the date of admission to hospital. ICD-10 codes I21.0-I21.4 were used to identify myocardial 
infarction in HES. ICD-10 codes I63.0-I63.9 were used to identify ischemic stroke in HES.  
 
Statistical analysis 
We used conditional Poisson regression to estimate the incidence rate ratio (IRR) of first myocardial 
infarction or stroke in the 91 days following acute exacerbation compared to stable periods.  
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We adjusted for age in one year age bands. In addition, as weather may be associated with both 
acute exacerbation[21] and myocardial infarction[22] or stroke[23], we adjusted for season (split 
into October-March and April-September).  
 
In addition to the main self-controlled case series analysis, we also used a non-parametric spline 
based self-controlled case series method[24]. The advantages of this method are that the time 
segments within the total risk period (91 days after an acute exacerbation) do not have to be pre-
specified, and that this method allows an easier visualisation of the evolution of the relative risk 
across the total 91 day risk period. 
 
Secondary analyses 
One of the assumptions of the self-controlled case series analysis is that the outcomes do not alter 
the probability of future exposure or result in censoring of the observation time. As myocardial 
infarction and stroke are associated with death, which would decrease the probability of further 
acute exacerbation and result in informative censoring, we conducted a sensitivity analysis similar to 
previous studies15, 16 to assess the potential impact of breaking this assumption. To do this, we 
repeated the main analysis in those whose follow up was not censored due to death first for at least 
6 months following myocardial infarction or ischemic stroke, and also in those whose follow up was 
not censored due to death for at least 12 months following myocardial infarction or ischemic stroke. 
 
The analysis was conducted using Stata 14.1MP and R 3.2.4.  
 
Ethics 
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The protocol for this research was approved by the Independent Scientific Advisory Committee 
(ISAC) for the Medicines & Healthcare Products Regulatory Agency (MHRA) Database Research 
(protocol numbers 15_226A and 17_060). Generic ethical approval for observational research using 
the CPRD with approval from ISAC has been granted by a Health Research Authority (HRA) Research 
Ethics Committee (East Midlands – Derby, REC reference number 05/MRE04/87). The protocol is 
available on request.  
 
Results 
In total, we included 5,696 participants in the study: 2,850 individuals who had a first myocardial 
infarction and at least one acute exacerbation, during the study period, and 3,466 with a first 
ischemic stroke and at least one acute exacerbation during the study period (Figure 2). 164 COPD 
participants were included in both analyses. The characteristics of the study participants are 
summarised in Table 1.  
 
Compared to stable periods, the 91 days following the onset of acute exacerbation were associated 
with a 65% increased risk of myocardial infarction (IRR 1.65, 95% CI 1.50-1.81) and a 51% increased 
risk of ischemic stroke (IRR 1.51, 95% CI 1.39-1.65). The increased risk peaked in the first 3 days post-
acute exacerbation onset for myocardial infarction and appeared to peak in the 4-7 days post onset 
for ischemic stroke (Figure 3). The risk gradually fell back to stable period level after 28 days for 
myocardial infarction, however appeared to remain elevated longer for ischemic stroke (Figure 3).  
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The associations of acute exacerbation and both myocardial infarction and ischemic stroke were 
modified by the severity of acute exacerbation (p-value for interaction <0.001 for both myocardial 
infarction and ischemic stroke), with the risk of myocardial infarction being over 2.5 times that of 
stable periods in the 91 days following a severe acute exacerbation, compared to 1.6 times that of 
stable periods for moderate events. The risk of ischemic stroke was 1.7 times that of stable periods 
following severe acute exacerbation, and 1.4 times that of stable periods following moderate acute 
exacerbation. The results of the non-parametric self-controlled case series analysis using spline 
regression are displayed in Figure 4 and confirm the patterns observed in the segmented analysis 
(Figure 3).  
 
The association of acute exacerbation with myocardial infarction was stronger among infrequent 
exacerbators compared to frequent exacerbators, with infrequent exacerbators having a 69% higher 
rate of myocardial infarction in the 91 days following onset of acute exacerbation compared to their 
stable periods, and frequent exacerbators having a 42% higher rate of myocardial infarction 
compared to their stable periods (p=0.009); and infrequent exacerbators having a 68% higher risk of 
ischemic stroke following acute exacerbation compared to 30% increase for frequent exacerbators 
(p<0.001) (Figures 5-6). This pattern was also apparent when using number of baseline acute 
exacerbation rather than the dichotomous phenotype, although more so for myocardial infarction 
than ischemic stroke. 
 
The association of acute exacerbation with myocardial infarction was also stronger for those with 
severe as compared to mild-to-moderate airflow limitation (GOLD grade 1-2 IRR 1.69, 95% CI 1.45-
1.98; GOLD grade 3-4 IRR 1.98, 95% CI 1.61-2.05; p=0.007). However, the association of acute 
exacerbation with ischaemic stroke was not modified by severity of airflow limitation (p=0.74). 
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We found that the association of acute exacerbation with myocardial infarction in the 91 days 
following acute exacerbation was higher for non-STEMIs (IRR 1.80, 95% CI 1.56-2.06) than for STEMIs 
(IRR 1.39, 95% CI 1.16-1.68)).  
 
Those with previous heart failure had a lower relative risk of myocardial infarction associated with 
acute exacerbation (IRR 1.06, 95% CI 0.76-1.47, compared to IRR 1.62, 95% CI 1.48-1.78, p=0.01), 
and those with previous angina had a lower risk of ischaemic stroke associated with acute 
exacerbation (IRR 1.55, 95% CI 1.41-1.70, compared to 1.37, 95% CI 1.12-1.67, p=0.01). There was 
some evidence that the association between acute exacerbation and ischemic stroke was lower 
among those using aspirin (IRR 1.28, 95% CI 1.10-1.50) compared to non-aspirin users (IRR 1.63, 95% 
CI 1.47-1.80, p=0.04). There was no modification of the associations between acute exacerbation 
and either myocardial infarction or stroke by other previous cardiovascular disease, cardiovascular 
drugs, COPD medicines, or influenza vaccine in the baseline period, or by age or sex (data for age 
and sex not shown).  
 
In the sensitivity analysis among individuals whose observation time was not censored by death 
following myocardial infarction or ischemic stroke, relative risks were slightly smaller than the main 
analysis (supplementary material). 
 
Discussion 
We found that the increased risks of myocardial infarction and ischemic stroke in the weeks 
following acute exacerbation were of greater magnitude and longer duration than previously 
estimated[11]. These associations were also stronger among those with a severe exacerbation 
requiring hospitalization. suggesting possible modifiers of the associations between acute 
exacerbation and both myocardial infarction and ischemic stroke risk. Our data suggest that those 
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with a history of more frequent exacerbations may be at lower risk of myocardial infarction and 
ischemic stroke following an acute exacerbation, and that the association between acute 
exacerbation and myocardial infarction may be stronger among those with more severe airflow 
obstruction. The association between acute exacerbation and ischemic stroke was weaker among 
aspirin users compared to non-aspirin users. 
 
We found an eight-fold risk of myocardial infarction in the first three days following hospitalised 
acute exacerbation, compared to a two-fold risk for moderate events, suggesting a dose-response 
relationship by severity of acute exacerbation. Additionally, our findings suggest that risk of 
myocardial infarction increases again at around 8-14 days after falling for the first 7 days following 
moderate but not severe acute exacerbation. This could be a chance finding, but the timing may 
correspond to secondary bacterial infection in those with a viral exacerbation[25].  
 
For ischemic stroke, we found a 43% increased risk of ischemic stroke in the first three days and a 
two-fold risk for severe acute exacerbation compared to stable periods, again suggesting a dose-
response relationship. The peak risk of ischemic stroke was in the 4-7 days following acute 
exacerbation onset at an 80% increased risk of ischemic stroke following GP treated acute 
exacerbation and almost a four-fold increased risk of ischemic stroke following hospitalised acute 
exacerbation.  
 
Previous studies have suggested that frequent exacerbators have a higher risk of myocardial 
infarction[11]. Our study found that the associations of acute exacerbation with the risks of 
myocardial infarction and ischemic stroke were lower for frequent exacerbators. Crucially, our study 
compared the relative risk of a myocardial infarction during acute exacerbation to a participant’s 
own stable period, not risk of myocardial infarction and ischemic stroke between individuals. One 
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explanation could be that frequent exacerbators have a higher risk of myocardial infarction  and 
ischemic stroke during stable periods (due to perhaps increased baseline inflammation[26]), and 
thus there is less of a relative difference between stable and exacerbation periods for them. Because 
the self-controlled case series design includes only people who have the outcome of interest, we 
were not able to measure absolute rates of myocardial infarction or ischemic stroke. 
 
Others have found that increased airflow limitation is associated with increased risk of myocardial 
infarction.[27] This is reflected in our finding that COPD patients with worse airflow limitation are 
more susceptible to the effects of acute exacerbation on risk of myocardial infarction than those 
with lesser limitation. There was no modification of the effect of acute exacerbation on risk of 
ischemic stroke by severity of airflow limitation, despite increased airflow limitation being associated 
with stroke. [28] Although there may be other differences between these patients, this finding 
points to the possibility that acutely worsening airflow limitation during acute exacerbation may be 
involved in the increased risk of myocardial infarction associated with acute exacerbation. This 
finding lends support to the idea that acute exacerbation may be a risk factor for type-2 myocardial 
infarction; which is the result of mismatch of myocardial supply and demand of oxygen, but not due 
to plaque rupture[29]. Coupled with our finding that the association between acute exacerbation 
and ischemic stroke (but not myocardial infarction) was stronger among aspirin non-users is also 
suggestive of different mechanisms driving risk of ischemic stroke and myocardial infarction 
following acute exacerbation.  
 
 
We found that those with a previous heart failure diagnosis had a lower relative risk of myocardial 
infarction associated with acute exacerbation. However, this is based on a small number of events in 
the at risk period and may be due to misclassification of episodes of breathlessness due to acute 
heart failure being misclassified as acute exacerbation in these patients thereby misclassifying 
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episodes of stable time as exposed time. Interestingly we also found a weaker association between 
acute exacerbation and ischemic stroke among those with prior angina, which is potentially due to 
an effect of treatment for angina. 
 
We have previously reported that people with COPD and acute myocardial infarction are more likely 
to have a non-STEMI than a STEMI, compared to people without COPD with acute myocardial 
infarction [30]. Our finding that the associations of acute exacerbation with myocardial infarction 
was greater for non-STEMIs may help explain these excess non-STEMIs in those with COPD.  
 
Our finding that acute exacerbation is associated with a transient increased risk of myocardial 
infarction confirms suggestions from previous work that acute exacerbation are associated with 
myocardial infarction[11, 12] and myocardial injury[31]. Our study also supports previous findings 
that exacerbating COPD patients have a higher risk of stroke compared to non-exacerbating patients 
over a 10 year follow up[13], and our results extend these findings by precisely identifying the timing 
and duration of increased risk. In a within-individual analysis of 426 COPD patients and using 
prescription of antibiotics and oral steroids as a definition of acute exacerbation, Donaldson et al. 
[11] also found an increased risk of myocardial infarction associated with acute exacerbation, but 
this was limited to the first 5 days following acute exacerbation onset. Donaldson et al. also 
investigated the risk of stroke following acute exacerbation and found a small increase risk after 49 
days following acute exacerbation. We found a significantly higher risk than that previously 
estimated in previous studies. Our large sample size and validated exposure measures may have 
allowed us to estimate a more precise effect size and duration of increased risk. 
 
Broadly, our results are comparable with those from Smeeth et al.[10], who investigated the 
relationship between lower respiratory tract infection (LRTI) and risks of myocardial infarction and 
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stroke in 20,921 people from the general population. Smeeth et al. reported an IRR of 4.95 (95% CI 
4.43-5.53) for myocardial infarction and IRR of 3.19 (95% CI 2.81-3.62) for stroke in the three days 
following LRTI, which declined towards baseline over time, but lasted more than 4 weeks. The higher 
relative risk of myocardial infarction and ischemic stroke following LRTI in the general population 
compared to acute exacerbation may be due to a smaller relative difference in inflammation 
between acute exacerbation/LRTI and stable periods for those with COPD. Alternatively, those with 
COPD may attend their general practitioner with milder LRTI (in terms of inflammatory burden) than 
would those from the general population.  
 
We did not find that beta-blockers, or statins modified the effect of acute exacerbation on risk of 
first myocardial infarction or ischemic stroke. These findings are is not evidence that these medicines 
do not prevent myocardial infarction or ischemic stroke associated with acute exacerbation, but 
suggest that the particular risk of myocardial infarction and ischemic stroke associated with acute 
exacerbation may not be mitigated by use of these medicine. Our findings do not suggest that beta 
blockers and statins do not attenuate risk overall, since we investigated the relative risk between 
periods of stability (baseline) and exacerbation. A COPD patient who has been vaccinated against 
influenza will have some protection from influenza, but an acute exacerbation can still occur and will 
still increase the risk of cardiovascular events in the short term. Similarly, while statins or aspirin will 
reduce the absolute risk of a cardiovascular event in an individual, they will not remove all risk, and a 
period of increased risk following an acute exacerbation will still occur. However, this finding might 
also be explained by the definition of medicine use. We defined medicine use at baseline rather than 
as a time-varying effect modifier as prescription of these drugs are very much more likely after acute 
myocardial infarction or ischemic stroke. Since we only included first myocardial infarctions in the 
analysis, this period would be associated with an apparent rate of myocardial infarction or ischemic 
stroke of zero, and as such would have resulted in bias had we used a time-varying definition of 
cardiovascular medicines. This approach, however, may have resulted in underestimation of any 
effect modification by these medicines.  It is worth noting that those patients in whom primary 
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prevention with these medicines was completely effective would have not been included in the 
study due to the case only nature of the design.  
 
Clinicians should be aware that their COPD patients will be at higher risk of myocardial infarction and 
ischemic stroke in the weeks following acute exacerbation, and that this risk is much higher for those 
hospitalised with acute exacerbation. Acute exacerbations are known to be associated with 
mortality in those with COPD, and our findings are another reason that clinicians should focus on 
preventing acute exacerbation. We speculate that those patients with higher exacerbation 
frequency are at lower risk of stroke/myocardial infarction following an exacerbation for two 
reasons; 1) as they have more frequent medical care and are more likely to have relevant co-
morbidities diagnosed and therefore be on more robust risk reduction strategies and 2) because 
frequent exacerbators have a heightened inflammatory response even in the stable state, their 
change in inflammation is less from baseline to exacerbation. This increased response to 
inflammatory stimuli among infrequent exacerbators may contribute to the increased risk of 
myocardial infarction and stroke. Such a hypothesis would only apply to relative risk increase 
between baseline and exacerbation periods, but will not be associated with an overall absolute risk 
of myocardial infarction and stroke which is higher among frequent exacerbators.  
 
Our findings suggest that acute exacerbation may explain some of the increased cardiovascular risk 
in those with COPD. However, the recently reported SUMMIT trial[32], which investigated the 
effects of vilanterol and fluticasone furoate, did not find a reduction in cardiovascular events despite 
a reduction in acute exacerbation. However, most of the SUMMIT population had previous coronary 
artery disease. It is difficult to disentangle the effects of treatment of acute exacerbation on 
myocardial infarction from the effects of acute exacerbation itself.  
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Our study had several strengths. Firstly, the within-individual nature of the study design minimizes 
confounding by factors such as sex, genetics, long term medicine use and socioeconomic status. Our 
study also used data from the CPRD which is broadly generalizable to the UK population. In addition, 
compared to previous studies, we used a validated definition of acute exacerbation in electronic 
health records which enabled us to accurately identify acute exacerbation and we used linked 
secondary care HES data to categorise them as moderate or severe. In addition, we obtained data on 
myocardial infarction and ischemic stroke events from both primary and linked HES data which 
allowed us to identify more myocardial infarction[33] and ischemic stroke. Another strength of our 
study was that, compared to previous work in similar populations, our sample size was significantly 
larger.  
 
Our study also has some weaknesses. In order to deal with time-varying confounders, we split time 
up into one year age bands and adjusted for these. In addition, we specifically adjusted for the 
effects of season. However, our study could still be susceptible to time-varying confounders if these 
correlated very closely in time with acute exacerbation, such as the use of treatments for acute 
exacerbation. Additionally, our study may have been susceptible to misclassification of acute 
exacerbation and myocardial infarction. We have previously demonstrated that people with COPD 
have delayed diagnosis of myocardial infarction[30], if these events are originally diagnosed as acute 
exacerbation, this may result in a spurious association between acute exacerbation and myocardial 
infarction. However, to reduce the impact of this bias we excluded the first day of acute 
exacerbation from the analysis, and used a validated algorithm for identifying acute 
exacerbation[14]. We are aware we may not have eliminated this bias completely, however; such a 
bias is very unlikely to explain a substantial proportion of the effect however, as the effect of acute 
exacerbation in the risk of myocardial infarction lasted for several weeks. We find it unlikely that 
stroke would be misclassified as acute exacerbation.  Whilst there is evidence that troponin may rise 
at the time of an acute exacerbation, we are also aware that people with COPD do not have as great 
a troponin rise at myocardial infarction as people without COPD. Thus, the misclassification may 
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occur in both directions. We have used validated definitions for acute exacerbation and validated 
myocardial infarction codes based on the work of others and so what we have defined as “events” 
are likely to be true exacerbations or myocardial infarction/stroke events.  
 
Conclusions 
Compared to stable periods, we found associations between acute exacerbation and increased risks 
of myocardial infarction and ischemic stroke in the four weeks following the exacerbation. The 
increased risk of acute vascular events following acute exacerbation was significantly higher for 
severe compared to moderate acute exacerbation. The association of acute exacerbation with 
myocardial infarction risk was higher for infrequent exacerbators, and for those with more severe 
airflow limitation, and was more strongly associated with non-STEMIs. The association of acute 
exacerbation with ischemic stroke risk was higher for infrequent exacerbators and weaker among 
aspirin non-users. 
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Figure 1. Diagram representing the study design. In this hypothetical example the patient has two exposed periods (acute exacerbation) during follow up 
and a first myocardial infarction within 91 days of the start of the second exposed period (acute exacerbation).  
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Figure 2.  Patient flow in the study. 
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Figure 3. Incidence rate ratios of first myocardial infarction or ischaemic stroke in risk periods after 
an acute exacerbation of COPD relative to stable periods and stratified by acute exacerbation 
severity 
p-value for interaction between moderate and severe acute exacerbation for risk of myocardial infarction <0.001 
p-value for interaction between moderate and severe acute exacerbation for risk of ischemic stroke <0.001 
IRR – incidence rate ratio. 
 
 
 
MI - moderate AECOPD (GP treated)
Total risk period (91 days)
1-3 days
4-7 days
8-14 days
15-28 days
29-91 days
MI - severe AECOPD (resulting in hospitalization)
Total risk period (91 days)
1-3 days
4-7 days
8-14 days
15-28 days
29-91 days
IS - moderate AECOPD (GP treated)
Total risk period (91 days)
1-3 days
4-7 days
8-14 days
15-28 days
29-91 days
IS - severe AECOPD (resulting in hospitalization)
Total risk period (91 days)
1-3 days
4-7 days
8-14 days
15-28 days
29-91 days
period
Risk
1.58 (1.46, 1.71)
1.96 (1.52, 2.52)
1.53 (1.19, 1.97)
1.98 (1.67, 2.36)
1.64 (1.41, 1.91)
1.15 (1.02, 1.29)
2.58 (2.26, 2.95)
8.00 (5.81, 11.01)
7.78 (5.82, 10.59)
4.78 (3.57, 6.40)
4.00 (3.14, 5.09)
1.01 (0.78, 1.31)
1.45 (1.33, 1.57)
1.43 (1.00, 2.04)
1.83 (1.38, 2.42)
1.60 (1.27, 2.02)
1.71 (1.43, 2.04)
1.41 (1.24, 1.60)
1.97 (1.66, 2.33)
3.39 (1.52, 7.58)
3.84 (1.99, 7.42)
3.71 (2.22, 6.19)
2.52 (1.59, 3.97)
1.17 (0.83, 1.67)
IRR (95% CI)
739
63
63
138
184
291
249
39
48
47
65
50
902
56
83
117
205
441
117
8
11
24
26
48
N
  
1.5 2 4 8 16
25 
 
 
 
Figure 4. A Risk of myocardial infarction associated with moderate (general practitioner treated) 
acute exacerbation; B Risk of myocardial infarction associated with severe (hospitalized) acute 
exacerbation; C Risk of ischaemic stroke associated with moderate (general practitioner treated) 
acute exacerbation; and D Risk of ischaemic stroke associated with severe (hospitalized) acute 
exacerbation 
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Figure 5: Incidence rate ratios of first myocardial infarction in risk period (91 days) after an acute 
exacerbation of COPD relative to stable periods stratified by COPD patient characteristics 
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Figure 6: Incidence rate ratios of first ischaemic stroke in risk period (91 days) after an acute 
exacerbation of COPD (relative to stable periods stratified by COPD patient characteristics 
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Table 1. Characteristics of study participants with myocardial infarction or ischemic stroke and acute exacerbation of COPD during the study period  
Characteristic Myocardial infarction  Ischaemic stroke  
No. of participants 2,850 3,466 
Age at index myocardial infarction/ischemic stroke, years 73.3 (66.0-80.3) 75.8  (68.8-81.8) 
Average observation time from follow-up start, years 8.2 (6.0-10.3) 6.3 (3.9-9.0) 
Male sex 59.5% 55.1% 
Number with at least one severe event (acute 
exacerbation requiring hospitalisation) 
51.0% 36.1% 
Frequent exacerbators, 12mo prior to follow-up start 42.9% 39.5% 
Cardiovascular comorbid disease at any time prior to the 
start of follow up 
  
Angina 17.9% 17.2% 
Heart failure 7.7% - 
Stroke 5.7% - 
Atrial fibrillation - 19.0% 
Myocardial infarction - 7.2% 
Prescribed cardiovascular drug within 12 months prior to 
the start of follow-up 
  
Statin 29.4% 30.5% 
Aspirin 28.6% 30.6% 
Beta-blocker 20.7% 23.7% 
GOLD stage of airflow limitation at start of follow-up 
(N=1476) 
  
Grade 1-2, n (%) 976  
(64.1) 
978  
(65.3) 
Grade 3-4, n (%) 547  
(35.9) 
519  
(34.7) 
Missing, n 1,374 1,513 
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Prescribed respiratory drug, 12 months prior to the start 
of follow up 
  
ICS users  60.8% 42.1% 
- Concomitant LABA 79.8% 72.4% 
- Concomitant LAMA 34.5% 29.0% 
Non ICS users  39.2% 57.9% 
- LABA 14.1% 34.8% 
- LAMA 16.0% 22.8% 
Baseline influenza vaccination status 69.3% 72.6% 
Type of myocardial infarction (N=1872)   
STEMI, n (%) 734  
(37.2) 
- 
Non-STEMI, n (%) 1,242  
(62.9) 
- 
Missing, n 978 - 
Data are median (interquartile range) or percentage 
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Table S1 Medical codes used to identify myocardial infarction in CPRD. 
Medical code Read term 
241 acute myocardial infarction 
1204 heart attack 
1677 mi - acute myocardial infarction 
1678 inferior myocardial infarction nos 
5387 other specified anterior myocardial infarction 
10562 acute non-st segment elevation myocardial infarction 
12229 acute st segment elevation myocardial infarction 
14658 acute myocardial infarction nos 
14897 anterior myocardial infarction nos 
14898 lateral myocardial infarction nos 
23892 posterior myocardial infarction nos 
29758 acute transmural myocardial infarction of unspecif site 
32854 acute posterolateral myocardial infarction 
34803 other acute myocardial infarction 
46017 other acute myocardial infarction nos 
63467 true posterior myocardial infarction 
96838 [x]acute transmural myocardial infarction of unspecif site 
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Table S2 Medical codes used to identify ischaemic stroke in CPRD. 
Medical code Read term 
94482 [x]cereb infarct due unsp occlus/stenos precerebr arteries 
91627 [x]cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
92036 [x]occlusion and stenosis of other cerebral arteries 
90572 [x]occlusion and stenosis of other precerebral arteries 
53745 [x]other cerebral infarction 
19280 anterior cerebral artery syndrome 
32447 basilar artery occlusion 
8443 brain stem stroke syndrome 
25615 brainstem infarction 
15252 brainstem infarction nos 
4240 carotid artery occlusion 
39344 cereb infarct due cerebral venous thrombosis, nonpyogenic 
40758 cereb infarct due unsp occlus/stenos precerebr arteries 
5602 cerebellar infarction 
17322 cerebellar stroke syndrome 
8837 cerebral arterial occlusion 
15019 cerebral embolism 
34758 cerebral embolus 
23671 cerebral infarct due to thrombosis of precerebral arteries 
27975 cerebral infarction due to embolism of cerebral arteries 
24446 cerebral infarction due to embolism of precerebral arteries 
36717 cerebral infarction due to thrombosis of cerebral arteries 
3149 cerebral infarction nos 
16517 cerebral thrombosis 
33543 cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
5363 cva - cerebral artery occlusion 
40053 generalised ischaemic cerebrovascular disease nos 
12555 generalised ischaemic cerebrovascular disease nos 
569 infarction - cerebral 
57495 infarction - precerebral 
26424 infarction of basal ganglia 
9985 left sided cerebral infarction 
18689 middle cerebral artery syndrome 
98642 multiple and bilateral precerebral arterial occlusion 
57527 occlusion and stenosis of anterior cerebral artery 
55602 occlusion and stenosis of cerebellar arteries 
51759 occlusion and stenosis of middle cerebral artery 
65770 occlusion and stenosis of posterior cerebral artery 
71274 occlusion+stenosis of multiple and bilat cerebral arteries 
51326 other precerebral artery occlusion 
19260 posterior cerebral artery syndrome 
45781 precerebral arterial occlusion 
71585 precerebral artery occlusion nos 
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33499 pure motor lacunar syndrome 
51767 pure sensory lacunar syndrome 
10504 right sided cerebral infarction 
6155 stroke due to cerebral arterial occlusion 
4152 thrombosis, carotid artery 
40847 vertebral artery occlusion 
73901 [x]cerebrovascular diseases 
70536 acute cerebrovascular insufficiency nos 
10062 cerebrovascular disease nos 
47607 cva - cerebrovascular accident in the puerperium 
6116 cva - cerebrovascular accident unspecified 
1298 cva unspecified 
7780 left sided cva 
37493 other cerebrovascular disease nos 
34117 other cerebrovascular disease os 
51311 other specified cerebrovascular disease 
12833 right sided cva 
98188 small vessel cerebrovascular disease 
1469 stroke and cerebrovascular accident unspecified 
56279 stroke in the puerperium 
6253 stroke unspecified 
 
 
 
 
 
 
 
35 
 
Table S3 Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD relative to stable periods sensitivity analysis censoring within six months of 
myocardial infarction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk period N outcome events 
(myocardial infarction) 
IRR (95% CI) 
Total risk period (91 
days) 
695 1.53 (1.38-1.68) 
1-3 days 73 2.68 (2.11-3.41) 
4-7 days 66 1.91 (1.48-2.45) 
8-14 days 121 2.11 (1.74-2.56) 
15-28 days 172 1.80 (1.52-2.12) 
29-91 days 263 1.12 (0.97-1.29) 
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Table S4 Incidence rate ratios of first myocardial infarction in risk periods after an acute 
exacerbation of COPD relative to stable periods sensitivity analysis censoring within 12 months of 
myocardial infarction 
 
 
 
 
 
 
 
 
 
 
 
 
Risk period N outcome events 
(myocardial infarction) 
IRR (95% CI) 
Total risk period (91 
days) 
586 1.49 (1.34-1.67) 
1-3 days 59 2.48 (1.90-3.25) 
4-7 days 56 1.85 (1.41-2.44) 
8-14 days 104 2.08 (1.69-2.56) 
15-28 days 138 1.67 (1.39-2.01) 
29-91 days 229 1.14 (0.98-1.32) 
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Table S5. Incidence rate ratios of first ischaemic stroke in risk periods after an acute exacerbation of 
COPD relative to stable periods sensitivity analysis censoring within 6 months of ischemic stroke 
 
 
 
 
 
 
 
 
 
 
 
 
Risk period N outcome events 
(myocardial infarction) 
IRR (95% CI) 
Total risk period (91 
days) 
804 1. (1.-1.) 
1-3 days 47 1.54 (1.15-2.07) 
4-7 days 70 1.79 (1.40-2.28) 
8-14 days 119 1.80 (1.40-2.28) 
15-28 days 185 1.65 (1.41-1.93) 
29-91 days 383 1.35 (1.20-1.52) 
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Table S6. Incidence rate ratios of first ischaemic stroke in risk periods after an acute exacerbation of 
COPD relative to stable periods sensitivity analysis censoring within 12 months of ischemic stroke 
 
 
 
 
 
 
 
 
 
 
Risk period N outcome events 
(myocardial infarction) 
IRR (95% CI) 
Total risk period (91 
days) 
749 1.52 (1.38-1.68) 
1-3 days 43 1.53 (1.13-2.08) 
4-7 days 61 1.69 (1.31-2.20) 
8-14 days 112 1.84 (1.51-2.24) 
15-28 days 170 1.64 (1.39-1.94) 
29-91 days 363 1.39 (1.24-1.57) 
